Arbutus Biopharma, a biopharmaceutical company, received the go ahead to commence the Phase 1a/1b clinical trial of AB-836, its proprietary oral capsid inhibitor …
In a research report released Friday, Chardan analyst Madhu Kumar reiterated a Sell rating on shares of Arbutus Biopharma Corp (NASDAQ:ABUS), after the company …
